APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Peptide

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Therapeutic Peptide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025191 pages

Choose your research edition.

Industry ResearchTherapeutic Peptide Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Peptide Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Therapeutic Peptide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Peptide Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Peptide Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Therapeutic Peptide market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Therapeutic Peptide include Takeda, Teva, Sanofi, Johnson and Johnson, Novartis, Novo Nordisk, Merck, Eli Lilly and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Therapeutic Peptide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Peptide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Peptide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Peptide market size, projected growth trends, production technologies, key applications, and end-use industries.

Therapeutic Peptide Segment by Company

Takeda

Teva

Sanofi

Johnson and Johnson

Novartis

Novo Nordisk

Merck

Eli Lilly

AbbVie

AstraZeneca

Ipsen

Therapeutic Peptide Segment by Type

Oral

Injection

Other

Therapeutic Peptide Segment by Application

Central Nervous System

Metabolic Disorders

Cancer

Other

Therapeutic Peptide Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Therapeutic Peptide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Therapeutic Peptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Therapeutic Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Therapeutic Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Peptide Industry Trends Table 2. Therapeutic Peptide Industry Drivers Table 3. Therapeutic Peptide Industry Opportunities and Challenges Table 4. Therapeutic Peptide Industry Restraints Table 5. Global Therapeutic Peptide Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Therapeutic Peptide Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Therapeutic Peptide Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Therapeutic Peptide Sales Market Share by Manufacturers Table 9. Global Therapeutic Peptide Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Therapeutic Peptide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Therapeutic Peptide Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Therapeutic Peptide Manufacturers, Product Type & Application Table 13. Global Therapeutic Peptide Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Therapeutic Peptide by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Injection Table 18. Major Manufacturers of Other Table 19. Global Therapeutic Peptide Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Therapeutic Peptide Sales by Type (2021-2026) & (K Units) Table 21. Global Therapeutic Peptide Sales by Type (2027-2032) & (K Units) Table 22. Global Therapeutic Peptide Sales Market Share by Type (2021-2026) Table 23. Global Therapeutic Peptide Sales Market Share by Type (2027-2032) Table 24. Global Therapeutic Peptide Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Therapeutic Peptide Revenue by Type (2021-2026) & (K Units) Table 26. Global Therapeutic Peptide Revenue by Type (2027-2032) & (K Units) Table 27. Global Therapeutic Peptide Revenue Market Share by Type (2021-2026) Table 28. Global Therapeutic Peptide Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Central Nervous System Table 30. Major Manufacturers of Metabolic Disorders Table 31. Major Manufacturers of Cancer Table 32. Major Manufacturers of Other Table 33. Global Therapeutic Peptide Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Therapeutic Peptide Sales by Application (2021-2026) & (K Units) Table 35. Global Therapeutic Peptide Sales by Application (2027-2032) & (K Units) Table 36. Global Therapeutic Peptide Sales Market Share by Application (2021-2026) Table 37. Global Therapeutic Peptide Sales Market Share by Application (2027-2032) Table 38. Global Therapeutic Peptide Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Therapeutic Peptide Revenue by Application (2021-2026) & (K Units) Table 40. Global Therapeutic Peptide Revenue by Application (2027-2032) & (K Units) Table 41. Global Therapeutic Peptide Revenue Market Share by Application (2021-2026) Table 42. Global Therapeutic Peptide Revenue Market Share by Application (2027-2032) Table 43. Global Therapeutic Peptide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Therapeutic Peptide Sales by Region (2021-2026) & (K Units) Table 45. Global Therapeutic Peptide Sales Market Share by Region (2021-2026) Table 46. Global Therapeutic Peptide Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Therapeutic Peptide Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Therapeutic Peptide Sales by Country (2021-2026) & (K Units) Table 50. North America Therapeutic Peptide Sales by Country (2027-2032) & (K Units) Table 51. Europe Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Therapeutic Peptide Sales by Country (2021-2026) & (K Units) Table 53. Europe Therapeutic Peptide Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Therapeutic Peptide Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Therapeutic Peptide Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Therapeutic Peptide Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Therapeutic Peptide Sales by Country (2027-2032) & (K Units) Table 60. Global Therapeutic Peptide Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Therapeutic Peptide Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Therapeutic Peptide Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Therapeutic Peptide Revenue Market Share by Region (2021-2026) Table 64. Global Therapeutic Peptide Revenue Market Share by Region (2027-2032) Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda Therapeutic Peptide Product Portfolio Table 69. Takeda Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Teva Therapeutic Peptide Product Portfolio Table 74. Teva Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sanofi Therapeutic Peptide Product Portfolio Table 79. Sanofi Recent Development Table 80. Johnson and Johnson Company Information Table 81. Johnson and Johnson Business Overview Table 82. Johnson and Johnson Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Johnson and Johnson Therapeutic Peptide Product Portfolio Table 84. Johnson and Johnson Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novartis Therapeutic Peptide Product Portfolio Table 89. Novartis Recent Development Table 90. Novo Nordisk Company Information Table 91. Novo Nordisk Business Overview Table 92. Novo Nordisk Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Novo Nordisk Therapeutic Peptide Product Portfolio Table 94. Novo Nordisk Recent Development Table 95. Merck Company Information Table 96. Merck Business Overview Table 97. Merck Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Merck Therapeutic Peptide Product Portfolio Table 99. Merck Recent Development Table 100. Eli Lilly Company Information Table 101. Eli Lilly Business Overview Table 102. Eli Lilly Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Eli Lilly Therapeutic Peptide Product Portfolio Table 104. Eli Lilly Recent Development Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AbbVie Therapeutic Peptide Product Portfolio Table 109. AbbVie Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. AstraZeneca Therapeutic Peptide Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Ipsen Company Information Table 116. Ipsen Business Overview Table 117. Ipsen Therapeutic Peptide Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Ipsen Therapeutic Peptide Product Portfolio Table 119. Ipsen Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Therapeutic Peptide Distributors List Table 123. Therapeutic Peptide Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Therapeutic Peptide Product Image Figure 2. Global Therapeutic Peptide Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Peptide Market Size (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Peptide Sales (2021-2032) & (K Units) Figure 5. Global Therapeutic Peptide Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Therapeutic Peptide Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Injection Image Figure 10. Other Image Figure 11. Global Therapeutic Peptide Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Therapeutic Peptide Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Therapeutic Peptide Sales Market Share by Type (2021-2032) Figure 14. Global Therapeutic Peptide Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Therapeutic Peptide Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Therapeutic Peptide Revenue Market Share by Type (2021-2032) Figure 17. Central Nervous System Image Figure 18. Metabolic Disorders Image Figure 19. Cancer Image Figure 20. Other Image Figure 21. Global Therapeutic Peptide Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Therapeutic Peptide Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Therapeutic Peptide Sales Market Share by Application (2021-2032) Figure 24. Global Therapeutic Peptide Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Therapeutic Peptide Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Therapeutic Peptide Revenue Market Share by Application (2021-2032) Figure 27. North America Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Therapeutic Peptide Sales Market Share by Country (2021-2032) Figure 29. U.S. Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Therapeutic Peptide Sales Market Share by Country (2021-2032) Figure 34. Germany Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Therapeutic Peptide Sales Market Share by Country (2021-2032) Figure 41. China Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Therapeutic Peptide Sales Market Share by Country (2021-2032) Figure 49. Brazil Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Therapeutic Peptide Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Therapeutic Peptide Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Therapeutic Peptide Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Therapeutic Peptide Revenue (2021-2032) & (US$ Million) Figure 60. North America Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Therapeutic Peptide Revenue (2021-2032) & (US$ Million) Figure 62. Europe Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Therapeutic Peptide Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Therapeutic Peptide Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Therapeutic Peptide Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Therapeutic Peptide Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
  • Other
Applications
  • Central Nervous System
  • Metabolic Disorders
  • Cancer
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • AbbVie
  • AstraZeneca
  • Ipsen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Therapeutic Peptide Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Therapeutic Peptide Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Therapeutic Peptide Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Therapeutic Peptide Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Therapeutic Peptide Market Dynamics
  1. 2.1 Therapeutic Peptide Industry Trends
  2. 2.2 Therapeutic Peptide Industry Drivers
  3. 2.3 Therapeutic Peptide Industry Opportunities and Challenges
  4. 2.4 Therapeutic Peptide Industry Restraints
3 Therapeutic Peptide Market by Manufacturers
  1. 3.1 Global Therapeutic Peptide Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Therapeutic Peptide Sales by Manufacturers (2021-2026)
  3. 3.3 Global Therapeutic Peptide Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Therapeutic Peptide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Therapeutic Peptide Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Therapeutic Peptide Manufacturers, Product Type & Application
  7. 3.7 Global Therapeutic Peptide Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Therapeutic Peptide Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Therapeutic Peptide Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Therapeutic Peptide Tier 1, Tier 2, and Tier 3
4 Therapeutic Peptide Market by Type
  1. 4.1 Therapeutic Peptide Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.1.3 Other
  5. 4.2 Global Therapeutic Peptide Sales by Type
  6. 4.2.1 Global Therapeutic Peptide Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Therapeutic Peptide Sales by Type (2021-2032)
  8. 4.2.3 Global Therapeutic Peptide Sales Market Share by Type (2021-2032)
  9. 4.3 Global Therapeutic Peptide Revenue by Type
  10. 4.3.1 Global Therapeutic Peptide Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Therapeutic Peptide Revenue by Type (2021-2032)
  12. 4.3.3 Global Therapeutic Peptide Revenue Market Share by Type (2021-2032)
5 Therapeutic Peptide Market by Application
  1. 5.1 Therapeutic Peptide Application Introduction
  2. 5.1.1 Central Nervous System
  3. 5.1.2 Metabolic Disorders
  4. 5.1.3 Cancer
  5. 5.1.4 Other
  6. 5.2 Global Therapeutic Peptide Sales by Application
  7. 5.2.1 Global Therapeutic Peptide Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Therapeutic Peptide Sales by Application (2021-2032)
  9. 5.2.3 Global Therapeutic Peptide Sales Market Share by Application (2021-2032)
  10. 5.3 Global Therapeutic Peptide Revenue by Application
  11. 5.3.1 Global Therapeutic Peptide Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Therapeutic Peptide Revenue by Application (2021-2032)
  13. 5.3.3 Global Therapeutic Peptide Revenue Market Share by Application (2021-2032)
6 Global Therapeutic Peptide Sales by Region
  1. 6.1 Global Therapeutic Peptide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Peptide Sales by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Peptide Sales by Region (2021-2026)
  4. 6.2.2 Global Therapeutic Peptide Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Therapeutic Peptide Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Therapeutic Peptide Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Therapeutic Peptide Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Therapeutic Peptide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Therapeutic Peptide Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Therapeutic Peptide Revenue by Region
  1. 7.1 Global Therapeutic Peptide Revenue by Region
  2. 7.1.1 Global Therapeutic Peptide Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Therapeutic Peptide Revenue by Region (2021-2026)
  4. 7.1.3 Global Therapeutic Peptide Revenue by Region (2027-2032)
  5. 7.1.4 Global Therapeutic Peptide Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Therapeutic Peptide Revenue (2021-2032)
  8. 7.2.2 North America Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Therapeutic Peptide Revenue (2021-2032)
  11. 7.3.2 Europe Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Therapeutic Peptide Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Therapeutic Peptide Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Therapeutic Peptide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Therapeutic Peptide Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Therapeutic Peptide Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Therapeutic Peptide Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Therapeutic Peptide Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Therapeutic Peptide Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Therapeutic Peptide Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Therapeutic Peptide Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Therapeutic Peptide Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Therapeutic Peptide Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Therapeutic Peptide Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Ipsen
  62. 8.11.1 Ipsen Company Information
  63. 8.11.2 Ipsen Business Overview
  64. 8.11.3 Ipsen Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ipsen Therapeutic Peptide Product Portfolio
  66. 8.11.5 Ipsen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Therapeutic Peptide Value Chain Analysis
  2. 9.1.1 Therapeutic Peptide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Therapeutic Peptide Production Mode & Process
  6. 9.2 Therapeutic Peptide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Therapeutic Peptide Distributors
  9. 9.2.3 Therapeutic Peptide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst